Nestle will sell dietary supplements that counter the effects of weight loss drugs to “Ozempic Face”.
The company announced that it would launch products to “complement” weight loss treatments. These include hair growth supplements and electrolyte tablet that improves skin elasticity.
KitKat and Smarties maker is bracing for a drop in sales for ice cream and sweets due to the booming demand for products like Ozempic.
Anna Mohl is the CEO of Nestle Health Science Division. She told Bloomberg that it will keep up with changes in customer needs, such as “preserving lean muscles mass, managing digestion upset, and ensuring an adequate daily intake of micronutrients”.
The supplements should help combat the “Ozempic Face” . This is a side effect of taking semaglutide, a diabetes drug for weight loss. It causes the skin to lose its elasticity and the face to look gaunt.
The side effect is named after Novo Nordisk’s Ozempic treatment. This is a diabetes medication that is off-label used to treat obesity. Novo Nordisk makes Wegovy, a weight-loss medication that has proven to help patients lose 15pc on average.
In April, the Swiss skincare company Galderma said that it expected a surge in demand for fillers. This is because more people are starting to use obesity treatments and do not wish to lose weight on their faces.
Nestle’s move comes at a time when food manufacturers are preparing to counter the pressure on sales that more weight loss treatments will bring.
Mark Schneider, Nestle’s chief executive said last month that the company expected a drop in sales due to the drugs. The drugs work by suppressing the appetite.
He said: “In my case, it will be frozen foods, confectionery and to some degree ice cream.”
Nestle, the company that makes Haagen Dazs, has launched a new line of pastas and pies enriched with protein for those who are taking anti-obesity drugs.
Last month, it was said that these products provided “the right nutrition” – high proteins, good fiber, and the right minerals.
Recent studies suggest that patients who receive the treatment consume up to 30pc less calories.
Injections for obesity have seen a surge in sales over the last year. One in four US adults has taken GLP-1.
Novo Nordisk is racing to meet the high demand for these drugs. Wegovy is expected to be available on the NHS in the UK for up to 50,000 patients.
Novo Nordisk announced on Monday that it would spend $4.1bn to expand production of obesity drugs within the US. The company called this “one of the biggest manufacturing investments in Novo Nordisk history”.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.